-
Je něco špatně v tomto záznamu ?
Sketching the historical development of pyrimidones as the inhibitors of the HIV integrase
RV. Patel, YS. Keum, SW. Park,
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
- MeSH
- HIV-integrasa metabolismus MeSH
- inhibitory HIV-integrasy farmakologie MeSH
- lidé MeSH
- objevování léků metody MeSH
- pyrimidinony farmakologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Heterocyclic substances perform a very unique role in drug design and discovery. This article provides the primary objectives of the analysis within pyrimidine centered new heterocyclic elements chronologically from their finding focusing on one of the essential enzyme of HIV virus particle that is integrase upon suppressing its strand transfer function. The class of compounds reviewed here includes bicyclic pyrimidines, dihydroxypyrimidines, pyrimidine-2,4-dinones, N-methylpyrimidones, pyranopyrimidine, pyridine-quinoline conjugates, pyrimidine-2-carboxamides, N-3 hydroxylated pyrimidine-2,4-diones as well as their various substituted analogues. Such initiatives released an effective drug Raltegravir as a first FDA approved anti-HIV integrase inhibitor as well as several of its derivatives along with other pyrimidones is under clinical or preclinical growth. Some of the provided scaffolds indicated dual anti-HIV efficacies against HIV reverse transcriptase and integrase enzymes at both cites as 3'-processing and strand transfer, while several scaffolds exhibited potency against Raltegravir resistant HIV mutant strains determining themselves a potent class of compounds having appealing upcoming implementations. Connections of the new compounds' molecular structure and HIV viral target has been overviewed to be able to accomplish further growth of promising anti-HIV agents in future drug discovery process.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010761
- 003
- CZ-PrNML
- 005
- 20160413102631.0
- 007
- ta
- 008
- 160408s2015 fr f 000 0|engg|
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2014.07.005 $2 doi
- 024 7_
- $a 10.1016/j.ejmech.2014.07.005 $2 doi
- 035 __
- $a (PubMed)25084622
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Patel, Rahul V $u Organic Research Laboratory, Department of Bioresources and Food Science, College of Life and Environmental Sciences, Konkuk University, Seoul 143 701, South Korea; Laboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany ASCR & Palacký University, Šlechtitelů 27, 783 71 Olomouc, Czech Republic. Electronic address: rahul.svnit11@gmail.com.
- 245 10
- $a Sketching the historical development of pyrimidones as the inhibitors of the HIV integrase / $c RV. Patel, YS. Keum, SW. Park,
- 520 9_
- $a Heterocyclic substances perform a very unique role in drug design and discovery. This article provides the primary objectives of the analysis within pyrimidine centered new heterocyclic elements chronologically from their finding focusing on one of the essential enzyme of HIV virus particle that is integrase upon suppressing its strand transfer function. The class of compounds reviewed here includes bicyclic pyrimidines, dihydroxypyrimidines, pyrimidine-2,4-dinones, N-methylpyrimidones, pyranopyrimidine, pyridine-quinoline conjugates, pyrimidine-2-carboxamides, N-3 hydroxylated pyrimidine-2,4-diones as well as their various substituted analogues. Such initiatives released an effective drug Raltegravir as a first FDA approved anti-HIV integrase inhibitor as well as several of its derivatives along with other pyrimidones is under clinical or preclinical growth. Some of the provided scaffolds indicated dual anti-HIV efficacies against HIV reverse transcriptase and integrase enzymes at both cites as 3'-processing and strand transfer, while several scaffolds exhibited potency against Raltegravir resistant HIV mutant strains determining themselves a potent class of compounds having appealing upcoming implementations. Connections of the new compounds' molecular structure and HIV viral target has been overviewed to be able to accomplish further growth of promising anti-HIV agents in future drug discovery process.
- 650 _2
- $a objevování léků $x metody $7 D055808
- 650 _2
- $a HIV-integrasa $x metabolismus $7 D019427
- 650 _2
- $a inhibitory HIV-integrasy $x farmakologie $7 D019428
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a pyrimidinony $x farmakologie $7 D011744
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Keum, Young-Soo $u Organic Research Laboratory, Department of Bioresources and Food Science, College of Life and Environmental Sciences, Konkuk University, Seoul 143 701, South Korea. Electronic address: rational@konkuk.ac.kr.
- 700 1_
- $a Park, Se Won $u Organic Research Laboratory, Department of Bioresources and Food Science, College of Life and Environmental Sciences, Konkuk University, Seoul 143 701, South Korea. Electronic address: sewpark@konkuk.ac.kr.
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 97, č. - (2015), s. 649-63
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25084622 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20160413102715 $b ABA008
- 999 __
- $a ok $b bmc $g 1114190 $s 935129
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 97 $c - $d 649-63 $e 20140703 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- LZP __
- $a Pubmed-20160408